Phaseline

Targets › NDUFA10

NDUFA10 (NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 10, mitochondrial): drug programs, companies and trials

1 program from 1 company in 23 trials: 11 Phase 2, 5 Phase 1, 5 Phase 3, 2 Phase 4; Neurology, Cardiovascular, Genitourinary.

Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. (UniProt, O95299)

Open in Phaseline: the race on NDUFA10, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Boryung PharmaceuticalMetformin Hydrochloride
Mitochondrial complex I (NADH dehydrogenase) inhibitor; Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor
MT-ND6, NDUFA10, NDUFS8, MT-ND4L, NDUFA6Phase 1Diabetes Mellitus; Diabete Mellitus; Depression; Polycystic Ovary Syndrome …–

Conditions

Anatomic Stage I Breast Cancer AJCC v8 (2) Erythroplakia (2) Diabetes Mellitus (1) Diabete Mellitus (1) Depression (1) Polycystic Ovary Syndrome (1) Breast Atypical Ductal Hyperplasia (1) Non Small Cell Lung Cancer (1) Medulloblastoma, Childhood (1) Pre-Eclampsia Onset Less Than 37 Weeks (1) Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia (1) Lung Carcinoma (1)

Modalities

small molecule (1)

Companies

Boryung Pharmaceutical (1)

Related targets

MT-ND6 (1) NDUFS8 (1) MT-ND4L (1) NDUFA6 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.